Partnering revitalized at the BioFit2022...The partnering event BioFit2022 took place in Strasbourg, France on November 29th and 30th as well as online on December 7th and 8th. It reflected on challenging times in the pandemic, survivors’ of … more ➔
M&AEuropean Commission calls for reversal o... The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail. more ➔
partnershipBioNTech and Ryvu Therapeutics enter int...Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development … more ➔
M&AAmsterdam Neogene Therapeutics aquired b... AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that … more ➔
ObesityNovo Nordisk funds API manufacturing wit...Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials. more ➔
partnershipSOTIO licences first cancer ADC from Leg...SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc. more ➔
financingBritish AI provider raises $33m in Serie...London-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek. more ➔
Growing investor interest in biotechnologyLatest investment trends were presented by BIOTECH Insight at the start of the German Equity Forum more ➔
partnershipC4X Discovery Holdings inks $402m deal w...C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m. more ➔
financingCatalYm GmbH raises €50m to push visugro...Munich-based immunooncology specialist CatalYm GmbH wants to use €50m from a Series C financing round to advance its anti-GDF15 antibody to Phase II development. more ➔
